Physician profile
Erin E Reed
NPI 1730541442
$2,201.01
in general payments reported to CMS, 2019-2025
29 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $103 · 2021: $279 · 2022: $675 · 2023: $257 · 2024: $512 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $234.06 | 2020-2025 | Injectafer |
| Novo Nordisk INC | $233.37 | 2021-2025 | Wegovy |
| Exeltis, USA INC. | $175.40 | 2022-2025 | Slynd |
| Agile Therapeutics, INC. | $160.59 | 2021-2024 | Twirla |
| Gynesonics, INC. | $158.57 | 2022 | |
| Abbvie INC. | $103.23 | 2021-2024 | |
| Shield Therapeutics INC | $92.01 | 2022-2025 | Accrufer |
| Exact Sciences Corporation | $84.53 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $84.10 | 2022 | |
| Hologic Sales and Service, LLC | $74.86 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $74.35 | 2024-2025 | Myfembree |
| Organon LLC | $73.94 | 2023-2025 | Nexplanon |
| Astellas Pharma US INC | $73.00 | 2023-2024 | Veozah |
| Coopersurgical, INC. | $72.85 | 2021-2024 | Paragard T 380a, Mara Console |
| Pfizer INC. | $64.55 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $62.61 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $57.06 | 2022 | |
| Mayne Pharma Commercial LLC | $49.19 | 2023-2025 | |
| Millicent US INC | $42.11 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Channel Medsystems, INC. | $36.26 | 2022 | |
| Lilly USA, LLC | $32.94 | 2025 | Mounjaro, Zepbound |
| Aspira Women'S Health INC | $31.43 | 2021 | |
| Medtronic, INC. | $26.55 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.40 | 2021 | |
| Scynexis, INC. | $19.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.90 | 2021 | |
| Smith+Nephew, INC. | $19.40 | 2025 | Stravix Pl |
| Merck Sharp & Dohme LLC | $17.84 | 2024 | Gardasil, Gardasil 9 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.